Intravitreal brimonididine inhibits form-deprivation myopia in guinea pigs

Yifang Yang1,2†, Junshu Wu1†, Defu Wu2, Qi Wei1, Tan Zhong2, Jun Yang2, Xiaowei Yang1, Meizhen Zeng1 and Xingwu Zhong1,2*  

Abstract  
Background: The use of ocular hypotensive drugs has been reported to attenuate myopia progression. This study explores whether brimonidine can slow myopia progression in the guinea pig form-deprivation (FD) model.  
Methods: Three-week-old pigmented male guinea pigs (Cavia porcellus) underwent monocular FD and were treated with 3 different methods of brimonidine administration (eye drops, subconjunctival or intravitreal injections). Four different concentrations of brimonidine were tested for intravitreal injection (2 μg/μL, 4 μg/μL, 20 μg/μL, 40 μg/μL). All treatments continued for a period of 21 days. Tonometry, retinoscopy, and A-scan ultrasonography were used to monitor intraocular pressure (IOP), refractive error and axial length (AL), respectively. On day 21, guinea pigs were sacrificed for RNA sequencing (RNA-seq) to screen for associated transcriptomic changes.  
Results: The myopia model was successfully established in FD animals (control eye vs. FD eye, respectively: refraction at day 20, 0.97 ± 0.18 D vs. −0.13 ± 0.38 D, F = 6.921, P = 0.02; AL difference between day 0 and day 21, 0.29 ± 0.04 mm vs. 0.45 ± 0.03 mm, F = 11.655, P = 0.004). Among the 3 different brimonidine administration methods, intravitreal injection was the most effective in slowing myopia progression, and 4 μg/μL was the most effective among the four different concentrations of brimonidine intravitreal injection tested. The AL and the refraction of the brimonidine intravitreal injection group was significantly shorter or more hyperopic than those of other 2 groups. Four μg/μL produced the smallest difference in AL and spherical equivalent difference values. FD treatment significantly increased the IOP. IOP was significantly lower at 1 day after intravitreal injections which was the lowest in FD eye of intravitreal injection of brimonidine. At day 21, gene expression analyses using RNA-seq showed upregulation of Col1a1 and Mmp2 expression levels by intravitreal brimonidine.  
Conclusions: Among the 3 different administration methods, intravitreal injection of brimonidine was the most effective in slowing myopia progression in the FD guinea pig model. Intravitreal brimonidine at 4 μg/μL significantly reduced the development of FD myopia in guinea pigs. Expression levels of the Col1a1 and Mmp2 genes were significantly increased in the retinal tissues of the FD-Inj-Br group.  
Keywords: Brimonidine, Myopia, Form deprivation, Retina
Synopses
Among the 3 different administration methods (eye drops, subconjunctival or intravitreal injections), intravitreal injection of brimonidine was the most effective in slowing myopia progression in the form-deprivation guinea pig model. Intravitreal brimonidine at 4 μg/μL significantly reduced the development of form-deprivation myopia in guinea pigs. Expression levels of the Col1a1 and Mmp2 genes were significantly increased in the retinal tissues of the brimonidine intravitreal injection group.

Highlights
We evaluated the effects of 3 different forms of brimonidine administration and 4 different concentrations of brimonidine delivered via intravitreal injection in attenuating form-deprivation myopia in guinea pigs and found that axial growth and refraction difference value were significantly reduced in eyes receiving brimonidine intravitreal injection. We also investigated the molecular mechanisms underlying the attenuation of myopia development using RNA-seq and found that Col1a1 and Mmp2 expression levels were upregulated by brimonidine treatment.

Background
Myopia is a common public health problem that has far-reaching consequences and enormous potential economic impact [1, 2]. Anatomically, myopia is characterized by the excessive axial elongation of the eye [3]. Myopia that begins during middle childhood age is commonly known as school myopia [3]. As school myopia progresses to >−6.0 diopters (D) or an ocular axial length (AL) ≥26.0 or 26.5 mm, high myopia occurs. The presence of posterior staphyloma, which is the most common finding in patients with pathologic myopia, is the key differentiating factor between high and pathologic myopia [4]. The occurrence of staphyloma will, in most cases, eventually lead to other conditions, such as atrophic, traction or neovascular maculopathy [4], while high myopia itself can cause retinal detachment, cataract and increased risk of glaucoma [5].

Clinical studies have shown that low-concentration 0.01% atropine eye drops can effectively slow the progression of myopia [6, 7]. Atropine is generally believed to block the development of myopia by interacting with muscarinic acetylcholine receptors [8]. However, recent studies have shown that at the concentrations used to inhibit myopia in chicks and tree shrews, either the α1A- , α1D- , or α2A-adrenergic receptors might be the “true” intermediate receptors involved in atropine inhibition of myopia. This idea is based on a few different pieces of evidence. First, in Luft’s study, 18 different muscarinic antagonists were injected into goggled chick eyes to test whether they were effective at inhibiting myopia. Although Luft’s group identified another muscarinic antagonist, oxyphenonium, that prevents form-deprivation myopia (FDM), it was surprising that so many of the other antagonists were rather ineffective; 15 out of 18 tested had either a partial effect, were ineffective or toxic [9]. McBrien’s study demonstrated that the highly selective allosteric M4 muscarinic receptor antagonist MT-3 is effective at significantly inhibiting FDM in chicks and attributed this effect to mAChR M4 [8]. However, it has been reported by Näreoja that MT-3 also has modest to high-affinity for α1A- , α1D- or α2A-adrenoceptors [10]. Recently, Carr et al. demonstrated that MT-3, and other effective myopia-inhibiting mAChR antagonists atropine, pirenzepine and oxyphenonium, bound to the ADRA2A receptor with affinities that were sometimes lower than those for the chick mAChR M4 receptor, and these affinities matched the concentrations of drug required to inhibit myopia in chicks as reported by Luft et al. [11]. Carr’s group also tested the hypothesis that α-adrenoceptors might be involved in the regulation of eye growth in chicks by intravitreal injection of various ADRA2A agonists (clonidine, guanfacine and brimonidine) and an antagonist (yohimbine). They found that high concentrations of α2-adrenoceptor agonists, like those required by atropine, inhibited FDM in chicks [12]. Considering these, a strong possibility is that cholinergic receptors in the retina are not the main targets through which atropine and other muscarinic antagonists may act to prevent FDM.

Brimonidine, an α2-adrenergic agonist, has been reported in preliminary studies to inhibit the development of lens-induced myopia in mammal guinea pigs and FDM in non-mammal chicks [12, 13]. However, the mechanism of action of drugs varies among different species, and the mechanisms of lens-induced and FDM might be sufficiently different for them to respond differently to this agonist in the same species [14]. Therefore, we chose to investigate the action of brimonidine and associated transcriptomic changes in guinea pig eyes with FDM myopia. Further exploring the effectiveness of brimonidine as a treatment for myopia and of different routes of administration in a mammalian animal model could lead to the discovery of better pharmacotherapeutic targets for the prevention and treatment of human myopia.

Materials and methods
Animal housing, ethics statement and experimental procedure
Three-week-old male pigmented guinea pigs (Changsha Tianqin Biotechnology Corporation, Changsha, China) were housed at the Sun Yat-sen University Laboratory Animal Centre at 24 °C, on a 12:12 light-dark cycle with food, water and additional fresh vegetables provided ad-
libitum. Animal use protocols were approved by the Sun Yat-sen University Institutional Animal Care and Use Committee and followed the ARVO statement for the use of animals in ophthalmic and vision research.

A total of 130 animals were used in this study. All but 8 control animals were treated to induce FDM development in the right eye, and the same eye also underwent one of 10 treatments: form-deprivation (FD) only, eye drops (one drop, twice a day) of 4 μg/μL brimonidine or sterile water, subconjunctival injection of 4 μg/μL brimonidine or sterile water, or intravitreal injection of 2 μg/μL, 4 μg/μL, 20 μg/μL or 40 μg/μL brimonidine or sterile water. The animals received the treatments and FD induction simultaneously. Brimonidine tartrate (UK 14,304 tartrate; Sigma-Aldrich, St. Louis, Missouri, USA) was dissolved in sterile water at room temperature. Solutions were freshly prepared on the day of injection. A detailed flow chart can be found in Supplementary Fig. 2. First, we evaluated 16 animals in total from the two groups (FD group and control group, n = 8 each group) to test whether the FD model was successfully established. The FD group underwent FD in the right eye, while the control group did not. AL measurements were taken every 7 days and spherical equivalent (SE) measurements were taken every 10 days for 21 days, while intraocular pressure (IOP) was tested every two days for 21 days. Then, compared with the above FD group, we divided 48 animals into six treatment groups (eye drops of 4 μg/μL brimonidine or sterile water, subconjunctival injection of 4 μg/μL brimonidine or sterile water, intravitreal injection of 4 μg/μL brimonidine or sterile water, n = 8 each group) to examine the most effective brimonidine administration method. In this experiment, 48 animals underwent FD in the right eye. Eye drops were administered twice a day, one drop each time, while injections were administered every 4 days with 5 μL solution during the treatment period of 21 days, starting on day 0. AL was tested every 7 days for 21 days, while SE was tested every 10 days for 21 days. After that, we divided 30 animals into 5 groups (FD only, 2 μg/μL, 4 μg/μL, 20 μg/μL, 40 μg/μL, n = 6 each group) to evaluate the most effective concentration of intravitreal brimonidine. All 30 animals underwent FD in the right eye. Injections were administered every 4 days with 5 μL solution. AL and SE were tested every 10 days for 21 days. Finally, we divided 36 animals into 3 groups: FD, 4 μg/μL intravitreal injection of brimonidine and intravitreal injection of water (FD-No-Inj, FD-Inj-Br and FD-Inj-Wa, n = 12 per group). Injections were administered every 4 days with 5 μL solution. AL and SE were examined every week for 21 days, while IOP was tested every 2 days for 21 days. We compared only the right eyes of each group to avoid the potential influence of injections on the un.injected eyes.

**Induction of form-deprivation myopia and injections**

Circular Velcro rings covered with a diffuser were attached to the pericocular fur of the right eyes of animals under anesthesia by intraperitoneal injection of 2% pentobarbital sodium (30 mg/kg). Animals were monitored hourly during the 12-h-light period to ensure that the diffusers remained in place. The left eyes were left without diffusers. For injections, 5 μL of solution was injected into the right vitreous chamber or subconjunctival area using a microsyringe (Hamilton 700, 25 μL, Reno, USA) and bevelled needle (33 G) under the same anesthesia procedure. Injections were administered every 4 days from day 0; contralateral eyes were not injected.

**Optical and biometric measurements**

IOP, SE, and optical AL were measured in both eyes of restrained animals without anesthesia before the initiation of FD treatment (baseline), with follow-up measurements at two-day (IOP) or approximately weekly (SE and AL) intervals over 21 days. Only data from right eyes are reported here. IOP and AL were measured after topical anesthesia with 4% oxybuprocaine hydrochloride (Santen Pharmaceuticals, Osaka, Japan).

All IOP measurements were conducted prior to other procedures with rebound tonometry (iCare; Tonolab, Helsinki, Finland) around the same time of the day, early in the morning, after lights-on. Five measurements were taken for each eye, and the average was used for data analysis.

Refractive errors were measured using streak retinoscopy on awake animals in a dark room 30 min after instillation of 3 drops of 1% tropicamide phenylephrine ophthalmic solution (Saten, Osaka, Japan) at 5-min intervals to induce cycloplegia. SE values were calculated as the averages of results for the two principal meridians for use in data analyses.

Ocular axial dimensions were measured by A-scan ultrasonography with a 25-MHz probe (AXIS-II; Quantel Medical Inc., Clermont-Ferrand, France) assuming the velocity of sound in the anterior chamber was 1557.5 m/s, 1723.3 m/s in the lens, and 1540 m/s in the vitreous chamber [15]. For each measurement, at least five traces were captured per eye and analyzed offline. Only optical ALs are reported here, derived as the sum of anterior chamber depth, axial lens thickness and vitreous chamber depth.

**RNA-seq and bioinformatics analysis**

At day 21 of treatment, the retinas of 2 guinea pigs from each FD-Inj-Br, FD-Inj-Wa and FD-No-Inj groups were randomly selected for RNA-seq. Total RNA was extracted, and Smart-Seq2 [16–18] was used to purify poly-A+ transcripts. High-throughput sequencing was performed using an Illumina HiSeqTM 2000 instrument.
Establishment and validation of the FDM guinea pig model

The FD eyes showed significant ocular AL elongation and myopic shift in SE, as reflected in the progressive increase in each measurement and the difference values (i.e., the value of each measurement minus the value of the measurement on day 0) in FD eyes over the 21-day treatment period (Fig. 1a and b). As myopia progressed, the IOP in the FD myopic eyes gradually became higher than that in the control eyes (Fig. 1c). There were significant differences in IOP at time points before and after model establishment ($F = 8.811$, $P = 0.01$, Supplementary Table 1).

Statistically significant differences were found between the AL difference values at day 14 (control eye vs. FD
eye, 0.21 ± 0.05 mm vs. 0.39 ± 0.05 mm, F = 6.521, P = 0.023) and day 21 (control eye vs. FD eye, 0.29 ± 0.04 mm vs. 0.45 ± 0.03 mm, F = 11.655, P = 0.004) and the SE value at day 20 (control eye vs. FD eye, 0.97 ± 0.18 D vs. −0.13 ± 0.38 D, F = 6.291, P = 0.02). A statistical comparison between FD and control eyes is summarized in Supplementary Table 1. FD treatment significantly increased the IOP (control eye vs. FD eye, 11.02 ± 0.13 mmHg vs. 11.58 ± 0.13 mmHg, F = 5.456, P = 0.001).

**Intravitreal brimonidine effectively attenuated myopia**

To evaluate the efficacy of 4 μg/μL brimonidine in attenuating progressing myopia, 3 administration methods, eye drops and subconjunctival or intravitreal injections, were applied to deliver brimonidine to the FD eyes of guinea pigs. Intravitreal injection of brimonidine was found to be more effective than intravitreal injection of water and no-treatment control, while eye drops and subconjunctival injection groups showed no significant effect (Fig. 2, Supplementary Table 2). The AL of the intravitreal injection of the brimonidine group was significantly shorter than that of the intravitreal injection water and no-treatment control groups (brimonidine intravitreal injection vs. water intravitreal injection vs. no-treatment, 8.45 ± 0.02 mm vs. 8.55 ± 0.02 mm vs. 8.58 ± 0.02 mm, F = 9.370, P = 0.001). The SE of the intravitreal injection of the brimonidine group was significantly hyperopic compared with that of the intravitreal injection water and no-treatment control groups (brimonidine intravitreal injection vs. water intravitreal injection vs. no-treatment, 2.32 ± 0.30 D vs. 1.33 ± 0.30 D vs. 1.21 ± 0.30 D, F = 4.148, P = 0.030).

Among the 2 μg/μL, 4 μg/μL, 20 μg/μL and 40 μg/μL intravitreal brimonidine injections, 4 μg/μL was found to be the most effective in attenuating myopia progression in terms of AL elongation and SE myopic shift (Fig. 3, Supplementary Table 3). The 4 μg/μL group exhibited the shortest AL difference value at day 20 (2 μg/μL vs. 4 μg/μL vs. 20 μg/μL vs. 40 μg/μL, F = 9.149, P = 0.001; SE difference value: FD-Inj-Br vs. FD-Inj-Wa vs. FD-No-Inj, −2.96 ± 0.32 D vs. −4.04 ± 0.37 D vs. −4.50 ± 0.37 D, P < 0.001, Fig. 4, Supplementary Table 4). IOP was variable but was significantly lower at 1 day after intravitreal injections, and lowest in the FD-Inj-Br group (FD-Inj-Br vs. FD-Inj-Wa vs. FD-No-Inj, 9.149, P = 0.001; SE difference value: FD-Inj-Br vs. FD-Inj-Wa vs. FD-No-Inj, −2.96 ± 0.32 D vs. −4.04 ± 0.37 D vs. −4.50 ± 0.37 D, P < 0.001, Fig. 4c and Supplementary Table 4). Relevant mean baseline, AL and SE difference values and IOP data for the three groups are summarized in Supplementary Table 4.

To explore the patterns of the changes in IOP in different treatment groups during FDM establishment,
linear regression was performed on IOP data measured in FD eyes over 21 days. A regression analysis undertaken on FD-Inj-Br and FD-Inj-Wa data revealed a low-moderate linear correlation of AL with IOP (Fig. 5, \( r^2 = 0.505, P < 0.05 \)), providing indirect evidence for a role of IOP as an inflationary force in myopia development, which will be discussed further later.

### Differentially expressed genes (DEGs)

To explore gene expression in the retinal tissues of guinea pigs after intravitreal injection of brimonidine, transcriptome sequencing was performed on retinal tissues at day 21 of the experiment. We obtained retinal tissue with almost no choroid membrane (Supplementary Fig. 3a). First, we explored the expression levels of genes annotated as related to myopia in the Rat Genome Database (RGD), database in retinal tissues of guinea pigs in the FD-Inj-Br and FD-Inj-Wa groups. The results showed that the expression levels of the Col1a1 and Mmp2 genes were significantly increased (\( P < 0.05 \)) in the retinal tissues of the FD-Inj-Br group, and the expression level of Slc39a5 was significantly decreased (\( P < 0.05 \)), while there were no significant differences in the expression of other myopia-related genes between the two groups (Fig. 6a). Among the 25 adrenergic pathway-related genes, compared with the FD-Inj-Wa group, the Ptu gene was significantly higher in the FD-Inj-Br group, the Lmbrd2 gene was significantly lower in the FD-Inj-Br group, and the remaining 23 genes had no significant change. In the FD-Inj-Br group, compared with the FD-Inj-Wa group, 216 genes were upregulated, and 78 genes were downregulated (Fig. 6b, Supplementary Table 5). The functional enrichment of genes expressed at higher levels after intravitreal injection of brimonidine was obtained through GO analysis. The results showed that the upregulated genes were mainly enriched in terms related to angiogenesis, cell movement and migration and morphogenesis (Fig. 6c). In terms of overlap with the list of myopia-related genes, the genes upregulated in the FD-Inj-Br group showed significantly greater overlap than those upregulated in the FD-Inj-Wa group. Moreover, the upregulated genes were compared with the genes sets involved in the biological process of angiogenesis in the GSD and Mouse Genome Informatics (MGI) databases by Venn diagram (Fig. 6d); this analysis revealed two genes present in all three sets: Col1a1 and Mmp2 (Fig. 6d). Finally, we subjected the retinal tissue to immunohistochemical staining and analysis, and it was found that the expression levels of the Mmp2 protein in the retinal tissue was significantly higher in the FD-Inj-Br group than in the FD-Inj-Wa group, while no difference in the expression of Col1a1 was found between FD-Inj-Br and FD-Inj-Wa groups (Fig. 6e-f).

### Discussion

The main finding of this research is that intravitreal injection of brimonidine is effective in slowing the development of FDM in a mammalian model. In addition, brimonidine might affect the development of myopia by upregulating Col1a1 and Mmp2 gene expression in the retina.

To date, there have been 3 studies investigating the effects of intervention with adrenergic agonist drugs on myopia progression in animal models. However, the relationship between adrenergic receptors and myopia is still controversial. The three studies involved FD chickens, cell-receptor binding assays and lens-induced myopia in guinea pigs. The first two of the mentioned studies reported that muscarinic acetylcholine receptor (mAChR) antagonists block human \( \alpha_{2A} \)-adrenergic receptor (hADRA2A) signaling at concentrations comparable to those used to inhibit chick myopia in vivo and that high concentrations of \( \alpha_{2} \)-adrenoceptor agonists inhibited FDM in chicks [11, 12]. The latter of the three studies provided evidence that treatment with 0.1% brimonidine alone and 0.2% brimonidine alone, and not requiring the combination with pirenzepine, was effective in slowing the development of lens-induced myopia in guinea pigs, indicating that IOP elevation may be a promising mechanism for progressing myopia and suggesting potential treatment options [13].

The first question that this study sought to determine was whether brimonidine influences FD-induced myopia. The results of this study indicate that intravitreal injection of brimonidine can delay the progression of FDM in guinea pigs. One unanticipated finding was that not all modes of administration and not all concentrations of brimonidine are associated with delayed progression of myopia. Intravitreal injections of brimonidine were found to slow FDM progression, while eye drop instillation and subconjunctival injection did not. Moreover, a specific concentration of 4 \( \mu \)g/\( \mu \)L brimonidine was found to slow FDM progression, while 2 \( \mu \)g/\( \mu \)L, 20 \( \mu \)g/\( \mu \)L, and 40 \( \mu \)g/\( \mu \)L did not. The finding that only intravitreal injection can slow the progression of myopia is different from Liu’s published paper concerning lens-induced myopia (LIM) guinea pigs, in which eye drops were used [13]. In Liu’s study, 0.1% and 0.2% brimonidine were instilled into the guinea pig eye, one drop each time, twice a day, for 21 days, and they were effective at slowing the LIM in guinea pigs. One drop is approximately 20 \( \mu \)L; 0.1% concentration means 1 \( \mu \)L eye drop containing 1 \( \mu \)g brimonidine, while 0.2% means 1 \( \mu \)L eye drop containing 2 \( \mu \)g brimonidine. Thus, the 4 \( \mu \)g/\( \mu \)L concentration used is equal to 0.1% brimonidine in Liu’s work which was effective at slowing the development of LIM in guinea pigs. However, the mechanisms of LIM and FDM might be sufficiently
different to explain the difference in response. Similarly, it is also possible that the short duration of treatment in the animal model was insufficient and that significant differences might be observed for the other two methods of administration if longer treatment times were examined. In addition, this study suggested that there may be a “therapeutic window” of intravitreal brimonidine concentration. Since brimonidine was injected directly into the vitreous cavity, the drug was in direct contact with the retina. Here, we use the G protein

Fig. 2 Efficacy of different brimonidine administration methods in slowing form-deprivation myopia. a Axial length (AL) and spherical equivalent (SE) of refractive error of the subconjunctival injection method. b AL and SE of the eye drop method. c AL and SE of the intravitreal injection method. **P < 0.005, ***P < 0.001 (n = 8 each group). Only data from right eyes are reported here.
Fig. 3 Efficacy of different concentrations of intravitreal brimonidine in slowing form-deprivation myopia. a Change in spherical equivalent (SE) of refractive error difference value over the course of 20 days. b Change in axial length (AL) difference over the course of 20 days. *P < 0.05, **P < 0.005, (n = 6 each group). Only data from right eyes are reported here.

Fig. 4 Efficacy of intravitreal injection of brimonidine in slowing form-deprivation myopia. a Change in axial length (AL) difference over the course of 3 weeks. b Change in spherical equivalent (SE) of refractive error difference over the course of 3 weeks. c Change in intraocular pressure (IOP) over the course of 3 weeks. *P < 0.05, **P < 0.005, ***P < 0.001 (n = 12 each group). a indicates a significant difference between FD + Br and FD at P < 0.05, b indicates a significant difference between FD + Br and FD + Water at P < 0.05, c indicates a significant difference between FD + Water and FD at P < 0.05). Only data from right eyes are reported here.
switch-mediated negative feedback regulation model to explain the possible mechanism of brimonidine delaying the progression of FDM. In this model, we assume that there are three possible states when the cell experiences the direct or indirect action of brimonidine, namely, (i) full activation condition was not reached, (ii) activation was stronger than the negative feedback inhibition, or (iii) negative feedback inhibition was stronger than the activated state. When brimonidine does not reach a sufficient concentration to stimulate the cells, the downstream signaling pathways are not fully activated, so the lower concentration of brimonidine fails to delay the progression of myopia. When brimonidine reaches a certain therapeutic concentration, the cells on the retina are activated. Currently, although the mechanism of negative feedback inhibition also exists, it is not enough to exceed the activation effect, so the overall performance is a state where brimonidine plays a role in delaying the progression of myopia. However, if the dosage of brimonidine is further increased, the cells will receive a large amount of stimulation. At this time, the negative feedback inhibition regulation mechanism is activated, and the cells are in a state where the negative feedback inhibition is stronger than the activation, and thus a higher concentration of brimonidine does not delay the progression of myopia. We propose this hypothetical model based on the following three points: (i) We have observed that brimonidine only plays a role in delaying the progression of FDM at a certain concentration; (ii) Brimonidine is an α2-adrenergic receptor agonist, which is coupled to inhibitory Gi and Go proteins [21]; (iii) In G protein-coupled receptors, G protein conversion can mediate a negative feedback regulation mechanism [22]. In our model, when brimonidine is at a therapeutic concentration, G protein is activated to delay the progression of myopia. However, at higher concentrations, brimonidine may also mediate the activation of inhibitory G protein, thereby exerting inhibitory negative feedback regulation.

The common way to test whether a drug is associated with eye growth is by intravitreal injection, usually in extremely high concentrations, into the eyes of animal myopia models. The guinea pig is an ideal animal model for myopia research; its ocular structure is similar to that in humans, it has large pupils and reasonably large eyes, it is docile and cooperative, and its refraction and ocular biometrics are easily measured [23]. Therefore, our study aimed to further explore the hypothesis that α-adrenoceptors might be involved in the retinal regulation of eye growth in this powerful mammalian model.

Brimonidine, with effects on both aqueous inflow and uveoscleral outflow, is an ocular hypotensive drug. Previous studies on the correlation between IOP and myopia have produced inconsistent results. Some human studies have found no statistically significant difference between IOP in myopia and emmetropia [24], while others have found that IOP was significantly higher in severe myopes than in emmetropes and was correlated with the increase in AL [25]. Previous cross-sectional and prospective studies in children, addressing the question of whether IOP is related to myopia prevalence or progression have generally shown no such associations [24, 26, 27]. The SCORM (Singapore Cohort Study of the Risk Factors for Myopia) study found that IOP was not correlated with SE refraction and that there was no difference in pressure between refractive groups at baseline [24]. The Correction of Myopia Evaluation Trial (COMET) study reported that IOP was not associated with sex, baseline refractive error, baseline AL, myopia progression or change in AL, over the 5-year observation period [26]. Despite all these findings, it is well known that the elevated ocular pressure found in congenital glaucoma is associated with a higher rate of axial elongation in infant eyes [28]. It is still not known whether variations in the range of normal IOP could influence ocular growth and myopia development in school-age children. Furthermore, the results of a longitudinal experimental study of IOP in chicks under FDM or LIM were inconsistent [29].

The second aim of this study was to explore whether there is a correlation between IOP and myopia. In our study, we found a moderate positive relationship ($r^2 = 0.505, P < 0.05$) between the change in IOP and AL, and FD eyes showed a tendency of elevated IOP, which is consistent with the possibility that structural changes in myopic (FD) eyes can lead to IOP elevation. The results of this study confirm that there is a positive correlation between changes in IOP and changes in the AL in the guinea pig FD model, which is consistent with the results of a previous study [30]. The FD treatment causes
Fig. 6 (See legend on next page.)
the retinal image to be blurred during the development of the eyeball. According to these data, we may infer that the image blurring may further cause an increase in IOP. To normalize the IOP, the developing eyeball may increase in volume to achieve a decrease in IOP, thereby causing the AL of the eyeball to become longer to relieve the increase in IOP.

Further studies of treated guinea pig retinas were performed by RNA-seq to identify candidates for key genes and pathways in myopia. The Col1a1 and Mmp2 genes have been reported to encode the extracellular matrix component collagen and are engaged in extracellular matrix remodeling in the sclera [31, 32]. In addition, the proteins encoded by Col1a1 and Mmp2 are involved in angiogenesis and the myopia pathway (among other activities) in mice and guinea pigs [33–36]. Here, we found that the expression levels of these two genes were upregulated in the retina after the intravitreal injection of brimonidine. Although the GO analysis results indicate that most of the upregulated genes are related to angiogenesis, the retina of guinea pig, as an avascular tissue, does not generate blood vessels. Therefore, it is speculated that the role of these angiogenesis-promoting genes in the retina may be to promote the regeneration of certain cells or tissues. There are reports suggesting that Mmp2 is involved in retinal regeneration [37]. In addition, the genes up-regulated in the FD-Inj-Br group are enriched in the negative regulation of cell migration and morphogenesis-related terms, which suggests that the brimonidine-mediated delay in myopia progression may be associated with these biological functions. Further studies are needed to verify the mechanism by which brimonidine delays the progression of myopia. Furthermore, mutations in Slc39a5 have been identified as being associated with pathogenic high myopia in a few studies [38–40]. Slc39a5 encodes the solute carrier family 39 member 5, which is a key member of the ZIP transporters for metal ions, especially in mammalian zinc homeostasis [41]. The retina contains particularly high amounts of zinc, suggesting a pivotal role in the tissue [42]. Zn^{2+} dysregulation is a major factor limiting the survival and regenerative capacity of injured retinal ganglion cells (RGCs) [43]. In the FD-Inj-Br group, the expression of Slc39a5 was significantly decreased, which was 1/78 of the genes that were significantly down-regulated. However, GO analysis of these genes showed that they were not enriched in the current guinea pig GO-related terms. Therefore, with the support of existing data, we did not conduct further verification or mining on Slc39a5. Among the 25 adrenergic pathway-related genes, compared with the FD-Inj-Wa group, the expression of two genes changed significantly in the FD-Inj-Br group. The Pln gene was significantly increased in the FD-Inj-Br group, and Lmbrd2 gene was significantly reduced in the FD-Inj-Br group. Therefore, we speculate that brimonidine may not rely on the adrenergic pathway when delaying FDM.

The mechanism by which brimonidine delays FDM may act not only through IOP but also directly on the retina. Among the three modes of administration, intravitreal injection delivers the drug directly to the retina, and the effective concentration of the four concentrations is remarkably similar to that required to activate nerve receptors. Moreover, there are abundant retinal nerve receptors in the retina. Therefore, we hypothesize that brimonidine increases the expression of genes related to tissue regeneration in retinal tissues. These genes may improve the perception of blurred images in the retina in the FD model, thereby alleviating the occurrence of myopia. However, since the effect of image blurring cannot be eliminated, myopia cannot be suppressed, but only relieved.

With our research design, we are unable to strictly distinguish between actions on the adrenergic receptors and IOP. We found that intravitreal brimonidine could lower the IOP and slow myopia progression in FD eyes. RNA-sequencing data showed that at day 21, the expression of adrenergic signaling-related genes in the retina was not significantly different between the FDM-Inj-Br group and FDM-Inj-Wa group. Among the set of adrenergic signaling-related genes, 23 of 25 genes had no
significant difference in expression between groups. This indicated that the effect of slowing myopia progression by brimonidine may not occur through an adrenergic signaling-related pathway. Moreover, we found no implications for the site of action of atropine.

It cannot be overlooked that as many as 20–25% of genes whose functions have not been determined might also play a role in myopia. Although the guinea pig is often used to study myopia, its genome has not been fully characterized, and further genetic studies are needed.

We must recognize that there are some shortcomings in our experiment. All the samples of guinea pig retinas were collected 21 days after the induction of FDM. Consequently, by design, our study focused on identifying the effects of FD rather than its causes, which might be detected after much shorter intervals after initiating FD. Therefore, further research should be conducted to explore early changes in gene expression during FD and to extend analyses to other tissues in the retina-to-sclera signal transmission chain. Combined with bioinformatics research, future studies can explore regulatory pathways or networks and locate key regulatory factors in myopia. In addition, we found that most of the guinea pigs lost their diffusers one to two times per week, although no longer than 1 h at a time, which may have had some unexpected influence on the results. Moreover, the intervals between the tested doses of brimonidine (2 μg/μL, 4 μg/μL, 20 μg/μL and 40 μg/μL) were quite broad and future studies may evaluate more doses than the present study.

Conclusions
Among the three different administration methods (eye drops, subconjunctival injections, and intravitreal injections), brimonidine intravitreal injection was the most effective in slowing myopia progression in the FD guinea pig model. Intravitreal brimonidine (4 μg/μL) significantly reduced the development of FDM in guinea pigs. Expression levels of the Col1a1 and Mmp2 genes were significantly increased in the retinal tissues of the FD-Inj-Br group.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40062-021-00248-0.

Acknowledgements
The authors thank Professor William Kenyon Stell for his comments of earlier drafts of this manuscript and questions on research statistics and contributions to the writing, which have improved our own understanding of this field.

Authors' contributions
YY and JW collected, analyzed, and interpreted the animal data. YY was a major contributor in writing the manuscript. DW, QW, TZ and JY performed the ocular examination. XY and MZ performed RNA-seq and immunohistochemical analysis. XZ conceived the study and supervised the research. All authors read and approved the final manuscript.

Funding
This work was supported by grants from the National Natural Science Foundation of China (Grant No. 81870681) and the Natural Science Foundation of Hainan Province (Grant No. 817364).

Availability of data and materials
The datasets during and/or analyzed during the current study available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Animal use protocols were approved by the Sun Yat-sen University Institutional Animal Care and Use Committee.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 10 January 2021 Accepted: 24 May 2021
Published online: 14 July 2021

References
1. Naidoo KS, Fricke TR, Frick KD, Jong M, Naduvilath TJ, Resnikoff S, et al. Potential lost productivity resulting from the global burden of myopia: systematic review, meta-analysis, and modeling. Ophthalmology. 2019;126(3):338–46.
2. Modjtahedi BS, Ferris FL 3rd, Hunter DG, Fong DS. Public health burden and potential interventions for myopia. Ophthalmology. 2018;125(5):628–30.
3. Morgan IG, Ohno-Matsui K, Savé SM. Myopia. Lancet. 2012;379(9827):1739–48.
4. Ruiz-Medrano J, Montero JA, Flores-Moreno I, Arias L, García-Layana A, Ruiz-Moreno JM. Myopic maculopathy: current status and proposal for a new classification and grading system (ATN). Prog Retin Eye Res. 2019;69:80–115.
5. Ikuno Y. Overview of the complications of high myopia. Retina. 2017;37(12):2347–51.
6. Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113(12):2285–91.
7. Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119(2):347–54.

8. McBrien NA, Arunagiram B, Gentile A, Chow A, Sehebjiada S. The M4 muscarinic antagonist MT-3 inhibits myopia in chick: evidence for site of action. Ophthalmic Physiol Opt. 2011;31(5):529–39.

9. Luft WA, Ming Y, Stell WK. Variable effects of previously untested muscarinic receptor antagonists on experimental myopia. Invest Ophthalmol Vis Sci. 2003;44(3):1380–8.

10. Näreja K, Kukkonen JP, Rondinelli S, Tolvola DM, Meriluoto J, Näsman J. Adrenergic activity of muscarinic toxins identified from mamba venoms. Br J Pharmacol. 2011;164(2):538–50.

11. Carr BJ, Mihaeta K, Ramachandran R, Safedidine M, Nathanson NM, Stell WK, et al. Myopia-inhibiting concentrations of muscarinic receptor antagonists block activation of α2A-adrenoceptors in vitro. Invest Ophthalmol Vis Sci. 2018;59(7):2778–91.

12. Carr BJ, Nguyen CT, Stell WK. Alpha2-adrenoceptor agonists inhibit form-deprivation myopia in the chick. Clin Exp Optom. 2019;102(6):418–25.

13. Liu Y, Wang Y, Lv H, Jiang X, Zhang M, Li X. α2-adrenergic agonist brimonidine control of experimentally induced myopia in guinea pigs: a pilot study. Mol Vis. 2017;23:785–98.

14. Morgan KS, Ashby RS, Nickla DL. Form deprivation and lens-induced myopia: are they different? Ophthalmic Physiol Opt. 2013;33(3):655–61.

15. Jiang L, Zhang S, Schaeffel F, Xiong S, Zheng Y, Zhou X, et al. Interactions of chromatic and lens-induced defocus during visual control of eye growth in guinea pigs (Cavia porcellus). Vis Res. 2014;94:24–32.

16. Ramsköld D, Luo S, Wang YC, Li R, Deng Q, Faridani OR, et al. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol. 2012;30(8):777–82.

17. Picelli S, Björklund AK, Faridani OR, Sagasser S, Winberg G, Sandberg R. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat Methods. 2013;10(11):1096–8.

18. Picelli S, Faridani OR, Björklund AK, Winberg G, Sagasser S, Sandberg R. Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc. 2014;9(1):171–81.

19. Mertea P, Mertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 2013;31(3):290–5.

20. Varghese F, Buhlhar AB, Mahatra R, De A. IHC profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS One. 2014;9(5):e96801.

21. Zefirov TL, Faskhutdinov LI, Ziyatdinova NI, Galieva AM, Zefirov AL. Effect of stimulation of α2A-adrenergic receptors on action potential of working cardiomyocytes in rat atrium. Bull Exp Biol Med. 2019;167(5):603–5.

22. Tilley DG. G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function. Circ Res. 2011;109(2):17–30.

23. Schaeffel F, Feldkämper M. Animal models in myopia research. Clin Exp Optom. 2015;98(6):507–17.

24. Lee AJ, Saw SM, Gazzard G, Cheng A, Tan DT. Intraocular pressure associations with refractive error and axial length in children. Br J Ophthalmol. 2004;88(1):7–17.

25. Shen M, Fan F, Xue A, Wang J, Zhou X, Lu F. Bismutarchemic properties of the cornea in high myopia. Vis Res. 2008;48(21):2167–71.

26. Manny RE, Deng L, Crossnoe C, Gwiazda J, IOP, myopic progression and axial length in a COMET subgroup. Optom Vis Sci. 2008;85(2):97–105.

27. Manny RE, Mitchell GL, Cotter SA, Jones-Jordan LA, Kheirstrand RN, Mutti DO, et al. Intraocular pressure, ethnicity, and refractive error. Optom Vis Sci. 2011;88(12):1445–53.

28. Sampaolesi R, Caruso R. Ocular echometry in the diagnosis of congenital glaucoma. Arch Ophthalmol. 1982;100(4):574–7.

29. Schmid KL, Hills T, Abbott M, Humphries M, Pyne K, Wildsoet C. Relationship between intraocular pressure and eye growth in chick. Ophthalmic Physiol Opt. 2003;23(1):25–33.

30. El-Nimri NW, Wildsoet CF. Effects of topical latanoprost on intraocular pressure and myopia progression in young guinea pigs. Invest Ophthalmol Vis Sci. 2018;59(6):2644–51.

31. Inamori Y, Ota M, Inoko H, Okada E, Nishizaki R, Shiotta T, The COL1A1 gene and high myopia susceptibility in Japanese. Hum Genet. 2007;122(2):151–7.

32. Zhao F, Wu H, Reinach PS, Wu Y, Zhai Y, Li Y, et al. Up-regulation of matrix metalloproteinase-2 by scleral monocyte-derived macrophages contributes to myopia development. Am J Pathol. 2020;189(9):1888–908.

33. Zhou X, Ji F, An J, Zhao F, Shi F, Huang F, et al. Experimental murine myopia induces collagen type Iα1 (COL1A1) DNA methylation and altered COL1A1 messenger RNA expression in sclera. Mol Vis. 2012;18:1312–24.

34. Wang M, Yang ZK, Liu H, Li RQ, Liu Y, Zhong W. Genipin inhibits the scleral expression of mmp-29 and MMP2 and promotes COL1A1 expression in myopic eyes of guinea pigs. Graefes Arch Clin Exp Ophthalmol. 2020;258(5):1031–8.

35. Zhu C, Chen Q, Yuan Y, Li M, Ke B. Endothelial reticulum stress regulates scleral remodeling in a guinea pig model of form-degeneration myopia. J Ophthalmol. 2020;2006452.

36. Zhao F, Zhou Q, Reinach PS, Yang J, Ma L, Wang X, et al. Cause and effect relationship between changes in scleral matrix metalloproteinase-2 expression and myopia development in mice. Am J Pathol. 2018;188(8):1754–67.

37. Tucker BA, Redenti SM, Jiang C, Swift JS, Klassen HJ, Smith ME, et al. The use of progenitor cell/biodegradable MMP2-PLGA polymer constructs to enhance cellular integration and retinal repopulation. Biomaterials. 2010;31(9):19–19.

38. Guo H, Jin X, Zhu T, Wang T, Tong P, Tian L, et al. SLC39A5 mutations interfering with the BMP/TGF-β pathway in non-syndromic high myopia. J Med Genet. 2014;51(8):318–25.

39. Jiang D, Li J, Xiao L, Li S, Jia X, Sun W, et al. Detection of mutations in LRPA1, CTSL, LEPR1L1, ZNF64, SLC39A5, and SCO2 in 298 families with early-onset high myopia by exome sequencing. Invest Ophthalmol Vis Sci. 2014;55(13):39–45.

40. Feng CY, Huang XQ, Cheng XW, Wu RH, Lu F, Jin ZB. Mutational screening of SLC39A5, LEPR1L1 and LRPA1 in a cohort of 187 high myopia patients. Sci Rep. 2017;7(1):1120.

41. Wang F, Kim BE, Peiris MJ, Eide DJ. The mammalian Zip5 protein is a zinc transporter that localizes to the basolateral surface of polarized cells. J Biol Chem. 2004;279(49):51433–41.

42. Ugarte M, Osborne NN. Zinc in the retina. Prog Neurobiol. 2001;64(3):219–49.

43. Li Y, Anderogenen L, Yuki Y, Omura K, Yin Y, Gilbert HY, et al. Mobile zinc increases rapidly in the retina after optic nerve injury and regulates ganglion cell survival and optic nerve regeneration. Proc Natl Acad Sci U S A. 2017;114(2):E209–E218.